
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment
Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to commence Phase I/II ELEVATE-45-201 trial of ENTR-601-45 for treating Duchenne muscular dystrophy (DMD …